logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type [see all tables in this series...]

Part (iv) All clients with cannabis as primary drug: number of episodes reporting the stated drug as secondary

CountryOpioidsCocaineOther stimulantsHypnotics/sedativesHallucinogensVolatile substancesCannabisAlcoholOthers
Bulgaria113001020
Czech Republic13297121110354
Denmark8717728976319033415
Germany6381564380320478241135173114147
Ireland1318724342131413462
Greece57936235481151410
Spain111101025190512323154448
France49744230593812201966146
Italy3799254124116520073126
Cyprus432274000120
Latvia104601070
Luxembourg412000000
Malta142937481003
Netherlands16248166192130500163
Austria709215336354025218
Slovakia128721950231
Finland20261253141190
Sweden4020186102242013517
United Kingdom49618272419411162170745553102
Total247366608592119014543391362414687702

Notes:

 Data on secondary drug use are only collected among all treatment clients and not separately for new treatment clients. 

 ‘Opioids’ include: heroin, methadone, other opioids; ‘Cocaine’ includes: cocaine HCl, crack cocaine; ‘Stimulants’ include: amphetamines, MDMA and derivates, other stimulants: ‘Cannabis’ can include herb or resin. For each client up to four secondary drugs can be reported. 

 A number of the clients report using the same drug both as primary and secondary drug, particularly for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI Protocol for the drugs categories. 

 See also 'General notes for interpreting data’ on the Explanatory notes and help page

Sources:

 Reitox national reports 2007.  

(see the help page for information about formats etc.)

Page last updated: Monday, 14 July 2008